Literature DB >> 11739705

Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture.

Gabriele Neumann1, Heinz Feldmann, Shinji Watanabe, Igor Lukashevich, Yoshihiro Kawaoka.   

Abstract

Ebola virus, a prime example of an emerging pathogen, causes fatal hemorrhagic fever in humans and in nonhuman primates. Identification of major determinants of Ebola virus pathogenicity has been hampered by the lack of effective strategies for experimental mutagenesis. Here we exploit a reverse genetics system that allows the generation of Ebola virus from cloned cDNA to engineer a mutant Ebola virus with an altered furin recognition motif in the glycoprotein (GP). When expressed in cells, the GP of the wild type, but not of the mutant, virus was cleaved into GP1 and GP2. Although posttranslational furin-mediated cleavage of GP was thought to be an essential step in Ebola virus infection, generation of a viable mutant Ebola virus lacking a furin recognition motif in the GP cleavage site demonstrates that GP cleavage is not essential for replication of Ebola virus in cell culture.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11739705      PMCID: PMC135697          DOI: 10.1128/jvi.76.1.406-410.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

Review 1.  Redesign and genetic dissection of the rhabdoviruses.

Authors:  A Roberts; J K Rose
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

Review 2.  Paramyxovirus reverse genetics is coming of age.

Authors:  Y Nagai; A Kato
Journal:  Microbiol Immunol       Date:  1999       Impact factor: 1.955

3.  Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity.

Authors:  V E Volchkov; V A Volchkova; E Muhlberger; L V Kolesnikova; M Weik; O Dolnik; H D Klenk
Journal:  Science       Date:  2001-02-01       Impact factor: 47.728

4.  Product review. New mammalian expression vectors.

Authors:  B Moss; O Elroy-Stein; T Mizukami; W A Alexander; T R Fuerst
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

5.  Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies.

Authors:  H Ito; S Watanabe; A Takada; Y Kawaoka
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

Review 7.  Host cell proteases controlling virus pathogenicity.

Authors:  H D Klenk; W Garten
Journal:  Trends Microbiol       Date:  1994-02       Impact factor: 17.079

8.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

9.  Epitopes involved in antibody-mediated protection from Ebola virus.

Authors:  J A Wilson; M Hevey; R Bakken; S Guest; M Bray; A L Schmaljohn; M K Hart
Journal:  Science       Date:  2000-03-03       Impact factor: 47.728

10.  Infectious rabies viruses from cloned cDNA.

Authors:  M J Schnell; T Mebatsion; K K Conzelmann
Journal:  EMBO J       Date:  1994-09-15       Impact factor: 11.598

View more
  96 in total

1.  Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein.

Authors:  Sonja R Gerrard; Stuart T Nichol
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Evaluation of perceived threat differences posed by filovirus variants.

Authors:  Jens H Kuhn; Lori E Dodd; Victoria Wahl-Jensen; Sheli R Radoshitzky; Sina Bavari; Peter B Jahrling
Journal:  Biosecur Bioterror       Date:  2011-11-09

3.  Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture.

Authors:  Gert Zimmer; Karl-Klaus Conzelmann; Georg Herrler
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 4.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

5.  Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread.

Authors:  Kristina Maria Schmidt; Michael Schümann; Judith Olejnik; Verena Krähling; Elke Mühlberger
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

6.  Minigenome-based reporter system suitable for high-throughput screening of compounds able to inhibit Ebolavirus replication and/or transcription.

Authors:  Luke D Jasenosky; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

7.  Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription.

Authors:  Peggy Möller; Nonia Pariente; Hans-Dieter Klenk; Stephan Becker
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  Rift valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system.

Authors:  Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

9.  The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Authors:  Martina Trunschke; Dominik Conrad; Sven Enterlein; Judith Olejnik; Kristina Brauburger; Elke Mühlberger
Journal:  Virology       Date:  2013-04-11       Impact factor: 3.616

10.  The Role of the Charged Residues of the GP2 Helical Regions in Ebola Entry().

Authors:  Haiqing Jiang; Jizhen Wang; Balaji Manicassamy; Santhakumar Manicassamy; Michael Caffrey; Lijun Rong
Journal:  Virol Sin       Date:  2009-04       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.